Booster Shots and Additional Doses for COVID-19 Vaccines — What You Need to Know
The CDC has approved a second COVID-19 booster for people age 50 and older that can be given 4 months after a first booster.
African clinical trial denied access to key COVID drug Paxlovid
Supply shortages and limits on research leave low- and middle-income countries struggling to access Pfizer’s COVID-19 antiviral.
Omicron: What We Know About the Dominant Coronavirus Variant
Versions of Omicron are highly transmissible and less susceptible to vaccines, but seem to cause less severe illness and fewer deaths among those who are immunized.
Global vaccination must be swifter
Speeding up development of new vaccines won’t help much in the next pandemic, unless world leaders work faster to roll out vaccination globally.
COVID's 'silver lining': Research breakthroughs for chronic disease, cancer and the flu
The pandemic has led to vaccine advancements, new insights on the way respiratory viruses spread and a better understanding of the immune system
AbbVie and Scripps Research Announce Collaboration to Develop Antiviral Treatments for COVID-19
AbbVie (NYSE: ABBV) and Scripps Research announced a global collaboration to develop potential novel, direct-acting antiviral treatments for COVID-19.
Hundreds of COVID trials could provide a deluge of new drugs
Two years into the pandemic, the COVID-19 drugs pipeline is primed to pump out novel treatments — and fresh uses for familiar therapies.
South Africa's scientists boost global fight against COVID-19
The backroom scientists and clinician-researchers who actually enabled the saving of so many lives often go unmentioned
Covid-19: Delhi Court Rebukes Indian Government Over Oxygen Crisis
In voting shadowed by a catastrophic surge in coronavirus cases, the party of Prime Minister Narendra Modi lost a key state election. International aid has begun flowing into the country.
Pandemic Accelerates Trend Toward Remote Clinical Trials
When Christina Brennan initially planned a clinical trial to test the use of famotidine for treating mild COVID-19, she wrote a protocol that involved participants occasionally coming in for lab work at an internal medicine clinic. Enrollment in trials run by Brennan and her colleagues on hospitalized COVID-19 patients was waning following last spring’s surge, so she’d shifted her focus to studying COVID-19 patients who were fighting the disease at home.